Eyeworld CME Supplements

EW JUL 2013 - Supported by Bausch + Lomb

This is a supplement to EyeWorld Magazine that doctors can take a test after reading and receive CME credits for.

Issue link: http://cmesupplements.eyeworld.org/i/146117

Contents of this Issue

Navigation

Page 6 of 7

Key inflammation practice patterns and clinical opinions of ASCRS members A What percentage of your cataract patients has 1+ cells/flare or greater postoperatively? Percentage of survey respondents using the following pharmaceuticals at the following timeframes before and after cataract surgery: Steroids NSAIDs Antibiotics 3 days preop 19% 43% 43% 1 day preop 16% 32% 33% Intraop 27% 16% 40% 1 day postop 67% 42% 51% Do not use 5% 14% 3% How important do you believe that it is to use BOTH NSAIDs and corticosteroids to block the inflammatory cascade after cataract surgery, when indicated? t the 2013 ASCRS•ASOA Symposium & Congress, more than 1,000 physicians responded to an important new clinical trends survey that will continue to be assessed each year. The survey asked ASCRS members more than 85 key questions relating to current issues they face on a regular basis. The goal is to obtain opinion from a significant percentage of the membership and to have the results reviewed and interpreted by the ASCRS Clinical Committees. If the Committees determine there exists a gap between current programming and membership viewpoints, understanding or practice patterns, the information will be used to address future education efforts, both in the main program and through ASCRS' CME educational grants. Data collected from the annual survey will provide a solid basis for tracking ASCRS' progress in resolving these education gaps. Many topics related to post cataract surgery inflammation were a part of this survey. These included topics on the level of inflammation currently seen by ASCRS members, the impact of low to moderate inflammation on outcomes, current therapeutic trends, and perspectives on generic substitutions. When asked the normal levels of inflammation they would expect after cataract surgery, most responded that they would consider between trace to 1+ cell and flare at day 1 postop after cataract surgery as normal. Specifically, 56% view this level as normal, while 30% of members expect between zero and trace cell and flare postop on an average basis. Only 15% expect to see 1+ cell and flare in postop "normal" cataract patients. In another question, survey respondents were asked to move from their expected inflammation levels to the actual percentage of cataract patients they see who have 1+ cell and flare postoperatively. Sixteen percent have under 1% of patients at this 1+ cell/flare level, while 32% have under 2% at this level. On the other hand, 29% of respondents have 20% or more of their patients with 1+ cell/flare. So there seems to be a relatively wide variation in the incidence of moderate inflammation among survey respondents. The clinical impact of low to moderate ocular inflammation is often debated. When survey respondents were asked about the clinical impact of this level of inflammation, most agreed that it had a significant impact on variability in visual acuity and quality results (71%), visual recovery time (81%), or patient comfort and satisfaction (83%).

Articles in this issue

Archives of this issue

view archives of Eyeworld CME Supplements - EW JUL 2013 - Supported by Bausch + Lomb